Allogene Therapeutics Sets Timeline for ALPHA3 Enrollment Completion and Clinical Update
Allogene Therapeutics (ALLO) has outlined its strategic clinical roadmap, targeting the completion of enrollment for its ALPHA3 study by the end of 2027. The company also plans to provide a significant clinical update regarding this program in mid-2027. During the Q3 2026 management discussion, CEO Zachary Roberts announced the retirement of CFO Geoff Parker. This transition occurs as the company continues to advance its pipeline and manage its long-term clinical development milestones.
Tickers: $ALLO